|
| Year, (ref.) | Country | Drugs used | Number of patients | Follow-up period | ALT normalization (%) | HBV DNA undetectable (%) | MELD score | CTP score | HCC (%) | Liver transplantation (%) | Death (%) |
|
| 2018, Jang JW | Korea | ETV/LAM | 179/116 | 10 years | n.r. | <20 IU/ml
39.3% | Change from baseline
LAM –3.28
ETV –5.00 | Change from baseline
LAM –3.09
ETV –2.40 | 20.0% | 0-0.5y
10.5%
0.5-10 y | 0-0.5y
6.8%
0.5-10y
25.8% |
| 2017, Wan YM | China | LdT/LAM/ETV | 31/45/54 | 2 years | LdT 83.3%
LAM 64.3%
ETV 85.4% | <500 copies/ml
LdT 83.7%
LAM 65.3%
ETV 89.1% | Significantly improved compared to baseline. | Significantly improved compared to baseline. | LdT 15.0%
LAM 15.6%
ETV 14.8% | n.r. | LdT 20.0%
LAM 6.7%
ETV 12.7% |
| 2017, Lee SK | Korea | TDF | 57 | 1 year | 77.2% | <116 copies/ml
70.2% | Change from baseline –2.9 | Change from baseline –1.7 | n.r. | n.r. | 0% |
| 2012, Chan HL | Global | LdT/LAM | 116/116 | 2 years | LdT 61.4%
LAM 52.4% | <300 copies/ml
LdT 49.1%
LAM 39.5% | n.r. | D point
LdT 38.6%
LAM 40.4% | LdT 15%
LAM 16% | LdT 4.35%
LAM 3.48% | LdT 16%
LAM 22% |
| 2011, Liaw YF | Taiwan | ETV (1 mg)/ADV | 100/91 | 1 year | ETV 63%
ADV 46% | <300 copies/ml
ETV 57%
ADV 20% | Change from baseline
ETV –2.6
ADV –1.7 | Improvement
ETV 38%
ADV 36% | ETV 12%
ADV 20% | ETV 11%
ADV 3% | ETV 23%
ADV 33% |
| 2011, Liaw YF | Global | TDF/FTC+TDF/ETV | 45/45/22 | 1 year | TDF 56.8%
FTC+TDF 75.6%
ETV 54.5% | <400 copies/ml
TDF 70.5%
FTC+TDF 87.8%
ETV 72.7% | Change from baseline
TDF –2.0
FTC+TDF –2.0
ETV –2.0 | point
TDF 25.9%
FTC+TDF 48.0%
ETV 41.7% | n.r. | 5.6% | TDF 4.4%
FTC+TDF 4.4%
ETV 9.1% |
| 2010, Shim JH | Korea | ETV | 70 | 1 year | 76.4% | <51 copies/ml 89.1% | Change from baseline –2.3 | Change from baseline –1.5 | 6.9% | 4.3% | 12.9% |
| 2007, Schiff E | Global | ADV | 176 | 1 year | 77% | <1000 copies/ml 59% | Change from baseline –2.0 | n.r. | n.r. | n.r. | 14.0% |
| 2003, Hann HW | USA | LAM | 75 | 1 year | 55% | <0.7 MEq/ml 69% | n.r. | point 31% | n.r. | n.r. | 13.3% |
|
